ATAGI update following weekly Covid meeting 21 April

Department of Health

ATAGI statement

Latest recommendation updates

Recent ATAGI considerations

On Wednesday 20 April 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 19 April 2022, over 57 million doses of COVID-19 vaccines have been administered in Australia.

Use of Booster doses in adolescents aged 12-15 years

On 8 April 2022 TGA provisionally approved the Pfizer COVID-19 vaccine as a booster in people aged 12-15 years. ATAGI released advice that it does not recommend booster doses of Pfizer COVID-19 vaccine in this age group, at this time.

ATAGI is continuing to consider evidence on the benefits and risks of boosters in this age group including the epidemiology, adverse events, and evidence of groups at higher risk of severe disease or groups that will benefit from further doses. ATAGI will update recommendations if required.

ATAGI continues to recommend young people aged 5 to 15 years receive a primary course of a COVID-19 vaccine, including those who may have previously had COVID-19. For most people this is 2 doses, or 3 primary doses for people who are severely immunocompromised.

/Media Release. View in full here.